Introduction Pulmonary vascular dysfunction, pulmonary hypertension (PH), and resulting
right ventricular (RV) failure occur in many critical illnesses and may be associated with a …

The therapeutic promise of nitric oxide (NO), a potent vasodilator, remains uncertain for
adults, and licensed indications are restricted to pediatric practice. This review considers the …

Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic
diseases in neonates, infants, and older children and contributes to significant morbidity and …

The management of congenital heart disease has changed dramatically over the last 15
years and continues to evolve at a rapid pace. More than ever before contemporary practice …

Inhaled nitric oxide is a targeted pulmonary vasodilator that improves clinical outcomes for
newborn patients with persistent pulmonary hypertension of the newborn, and may be …

Pulmonary vascular disease can be defined as either a disease affecting the pulmonary
capillaries and pulmonary arterioles, termed pulmonary arterial hypertension, or a disease …

Cardiac arrest occurs at a higher rate in children with heart disease than in healthy children.
Pediatric basic life support and advanced life support guidelines focus on delivering high …

The pathogenesis of pulmonary hypertension is a complex multifactorial process that
involves the remodeling of pulmonary arteries. This remodeling process encompasses …

The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including
systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory …

cAMP is a second messenger that is found ubiquitously in mammalian cells. It serves to
transduce the action of a wide variety of hormones and neurotransmitters and can modulate …